<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nicox Sa — News on 6ix</title>
<link>https://6ix.com/company/nicox-sa-1</link>
<description>Latest news and press releases for Nicox Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 05:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nicox-sa-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d528f7beedb30cb6f6a51a.webp</url>
<title>Nicox Sa</title>
<link>https://6ix.com/company/nicox-sa-1</link>
</image>
<item>
<title>Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026</title>
<link>https://6ix.com/company/nicox-sa-1/news/reminder-last-exercise-day-for-nicox-june-2024-warrants-is-june-19-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/reminder-last-exercise-day-for-nicox-june-2024-warrants-is-june-19-2026-1</guid>
<pubDate>Mon, 20 Apr 2026 05:30:00 GMT</pubDate>
<description>Press Release Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026April 20, 2026 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today reminds holders of the warrants issued in June 2024 as part of the Company’s equity offering with preemptive rights that these warrants will expire on June 20, 2026. June 20 being a Saturday, the last effective date for trading or exercising the war</description>
</item>
<item>
<title>Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-highlights-positive-ncx-470-phase-3-data-confirming-therapeutic-profile-at-the-2026-american-glaucoma-society-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-highlights-positive-ncx-470-phase-3-data-confirming-therapeutic-profile-at-the-2026-american-glaucoma-society-annual-meeting</guid>
<pubDate>Tue, 24 Feb 2026 06:30:00 GMT</pubDate>
<description>Press Release Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual MeetingFebruary 24, 2026 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that positive data from the NCX 470 Phase 3 studies were highlighted in 2 podium presentations and a poster at the 2026 American Glaucoma Society (AGS) Annual Meeting (February 1</description>
</item>
<item>
<title>Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-announces-positive-feedback-from-pre-nda-meeting-with-us-fda-for-ncx-470-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-announces-positive-feedback-from-pre-nda-meeting-with-us-fda-for-ncx-470-1</guid>
<pubDate>Mon, 16 Feb 2026 06:30:00 GMT</pubDate>
<description>Press Release Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470 U.S. NDA submission on track for summer 2026Nicox to receive milestone payment from Kowa upon submission of the NDANDA submission based on Phase 3 clinical data showing NCX 470 lowered intraocular pressure by up to 10mmHg in patients with open-angle glaucoma or ocular hypertension February 16, 2026 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), a</description>
</item>
<item>
<title>Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-to-present-data-from-ncx-470-phase-3-studies-at-american-glaucoma-society-ags-annual-meeting-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-to-present-data-from-ncx-470-phase-3-studies-at-american-glaucoma-society-ags-annual-meeting-2026-1</guid>
<pubDate>Tue, 10 Feb 2026 06:30:00 GMT</pubDate>
<description>Press Release Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026February 10, 2026 – release at 7:30 am Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that phase 3 clinical study results, including two podium presentations, will be delivered at the upcoming American Glaucoma Society (AGS) Annual Meeting 2026 (February 19-22, 2026, Rancho Mirage, CA, U.S.A.</description>
</item>
<item>
<title>Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-announces-conference-attendance-in-h1-2026-and-upcoming-scientific-data-presentations-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-announces-conference-attendance-in-h1-2026-and-upcoming-scientific-data-presentations-1</guid>
<pubDate>Tue, 20 Jan 2026 06:30:00 GMT</pubDate>
<description>Press Release Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data PresentationsJanuary 20, 2026 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced participation in several key ophthalmology, financial and industry conferences in the first half of 2026 and key scientific data presentations at the upcoming American Glaucoma Society (AGS) Annual Meeting 2026. America</description>
</item>
<item>
<title>Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-announces-complete-repayment-of-kreos-capital-debt-and-extends-cash-runway-beyond-2027-with-new-additional-financing-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-announces-complete-repayment-of-kreos-capital-debt-and-extends-cash-runway-beyond-2027-with-new-additional-financing-1</guid>
<pubDate>Mon, 05 Jan 2026 06:30:00 GMT</pubDate>
<description>Press Release Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing Company’s position strengthened, enabling flexibility in strategic discussionsAll Kreos Capital secured debt repaid using cash on hand Unsecured bond financing of up to €4 million concluded with partner and shareholder, Vester FinanceCash runway extended beyond 2027 January 5, 2026 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Growth Paris</description>
</item>
<item>
<title>Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-completes-ncx-470-new-drug-application-key-data-generation-for-submission-as-planned-in-h1-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-completes-ncx-470-new-drug-application-key-data-generation-for-submission-as-planned-in-h1-2026-1</guid>
<pubDate>Tue, 16 Dec 2025 06:30:00 GMT</pubDate>
<description>Press Release Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026 All clinical trial and long-term stability data required for the preparation of the New Drug Applications (NDA) has been generated and analysedPre-NDA meeting1 with the U.S. Food and Drug Administration (FDA) in preparation; U.S. NDA submission on-track as planned in H1 2026 Submission of NDA in China similarly on track for 2026 December 16, 2025 – release at 7:30 am CETSophia Anti</description>
</item>
<item>
<title>Nicox Provides First Half 2025 Financial Results</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-provides-first-half-2025-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-provides-first-half-2025-financial-results-1</guid>
<pubDate>Thu, 23 Oct 2025 05:30:00 GMT</pubDate>
<description>Press Release Nicox Provides First Half 2025 Financial Results New Drug Application (NDA) submissions for NCX 470 expected in 2026 in the U.S. and ChinaCompany believes that it can finance its existing operations for at least 12 months and expects to fully repay existing financial debts in 2026 October 23, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the financial results for Nic</description>
</item>
<item>
<title>Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicoxs-ncx-470-demonstrates-sustained-efficacy-through-12-months-in-denali-clinical-trial-with-no-new-safety-observations-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicoxs-ncx-470-demonstrates-sustained-efficacy-through-12-months-in-denali-clinical-trial-with-no-new-safety-observations-1</guid>
<pubDate>Thu, 02 Oct 2025 05:30:00 GMT</pubDate>
<description>Press Release Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-planned analysis of the NCX 470 Denali trial completed NCX 470 maintains robust intraocular pressure lowering at 6, 9 and 12 monthsOther analyses broadly in line with the trends seen for Mont BlancData presentations planned for upcoming ophthalmology conferences October 2, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Gr</description>
</item>
<item>
<title>Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-expects-to-fully-repay-financial-debts-with-ncx-470-de-risked-and-globally-licensed-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-expects-to-fully-repay-financial-debts-with-ncx-470-de-risked-and-globally-licensed-1</guid>
<pubDate>Thu, 04 Sep 2025 05:30:00 GMT</pubDate>
<description>Press Release Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed Company expects to fully repay existing financial debts in 2026NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China Milestones payable on U.S. NDA submission and on approvalGlaukos extends NCX 1728 research agreement Future strategic options under consideration including collaborations or business combinationsQ&A for shareholders available on the Nicox website: Q&A September 4,</description>
</item>
<item>
<title>Nicox Announces Shareholder Q&A Webpage Available</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-announces-shareholder-qanda-webpage-available-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-announces-shareholder-qanda-webpage-available-1</guid>
<pubDate>Tue, 26 Aug 2025 05:30:00 GMT</pubDate>
<description>Press Release Nicox Announces Shareholder Q&A Webpage AvailableAugust 26, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that a new webpage “Q&A” is available on the company’s website, www.nicox.com, including information on the most frequently asked questions for shareholders in the form of a Q&A about Nicox and its business. The Q&A page can be reached here: Q&A Any investor qu</description>
</item>
<item>
<title>Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-announces-positive-results-from-the-ncx-470-phase-3-denali-trial-in-glaucoma-patients-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-announces-positive-results-from-the-ncx-470-phase-3-denali-trial-in-glaucoma-patients-1</guid>
<pubDate>Thu, 21 Aug 2025 05:30:00 GMT</pubDate>
<description>Press Release Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Achieving the primary endpoint in both Denali and the first NCX 470 Phase 3 trial, Mont Blanc, meets efficacy requirements for approval in the U.S. and ChinaNCX 470 was also superior to latanoprost in the reduction of intraocular pressure (IOP) from baseline (p<0.05) at 3 out of 6 timepoints and numerically greater at 5 out of 6 timepointsNCX 470 0.1% was safe and well tolerated New Drug App</description>
</item>
<item>
<title>Nicox Extends Existing Flexible Equity Financing</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-extends-existing-flexible-equity-financing-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-extends-existing-flexible-equity-financing-1</guid>
<pubDate>Fri, 08 Aug 2025 05:30:00 GMT</pubDate>
<description>Press Release Nicox Extends Existing Flexible Equity Financing 5 million shares added to the existing equity financing line with Vester Finance NCX 470 Denali confirmatory Phase 3 results expected mid-August to mid-September 2025 August 08, 2025 – release at 7:30 am Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced an extension of the PACEO1 equity line of financing entered into with Vester Finance on March 5, 2</description>
</item>
<item>
<title>Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicoxs-partner-kowa-initiates-ncx-470-phase-3-clinical-trial-in-japan-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicoxs-partner-kowa-initiates-ncx-470-phase-3-clinical-trial-in-japan-1</guid>
<pubDate>Tue, 05 Aug 2025 05:30:00 GMT</pubDate>
<description>Press Release Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in JapanTriggers a €2 million milestone payment to Nicox August 5, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Japanese partner, Kowa, has initia</description>
</item>
<item>
<title>Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-and-kowa-sign-key-agreement-worth-up-to-euro1915-million-for-exclusive-rights-to-glaucoma-treatment-ncx-470-in-us-and-all-unlicensed-territories-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-and-kowa-sign-key-agreement-worth-up-to-euro1915-million-for-exclusive-rights-to-glaucoma-treatment-ncx-470-in-us-and-all-unlicensed-territories-1</guid>
<pubDate>Thu, 17 Jul 2025 05:30:00 GMT</pubDate>
<description>Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 million upfront, with total potential development and commercial milestones, depending on Denali trial results, of up to €191.5 millionTiered royalties of up to 20% in the U.S., starting at a minimum of 8%, with tiered high single to double digit royalties elsewhere Kowa will assume full responsibility for the preparation and fi</description>
</item>
<item>
<title>Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial</title>
<link>https://6ix.com/company/nicox-sa-1/news/nicox-announces-last-patient-completes-the-ncx-470-denali-phase-3-clinical-trial-1</link>
<guid isPermaLink="true">https://6ix.com/company/nicox-sa-1/news/nicox-announces-last-patient-completes-the-ncx-470-denali-phase-3-clinical-trial-1</guid>
<pubDate>Mon, 30 Jun 2025 05:30:00 GMT</pubDate>
<description>Press Release Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025 New Drug Application (NDA) submission in the U.S. targeted for H1 2026 June 30, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient has completed the Denali Phase 3 trial, evaluating the efficacy and safety of NCX 470, i</description>
</item>
</channel>
</rss>